Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 7/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | IAPP | P10997 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9709753 | 0.97 | LTB4R2 (0.42) | LTB4R2AGTR1IAPPBRS3AGTR2 | |
| SCHEMBL9709552 | 0.92 | IAPP (0.40) | LTB4R2AGTR1IAPPBRS3AGTR2 | |
| SCHEMBL9709582 | 0.89 | IAPP (0.39) | LTB4R2AGTR1IAPP | |
| SCHEMBL6957300 | 0.85 | HSD11B1 (0.47) | AGTR1CYP3A4AGTR2 | |
| SCHEMBL6949197 | 0.85 | HSD11B1 (0.47) | AGTR1CYP3A4AGTR2 | |
| SCHEMBL6953051 | 0.84 | HSD11B1 (0.47) | AGTR1BRS3AGTR2 | |
| SCHEMBL8524519 | 0.83 | HSD11B1 (0.43) | AGTR1CYP3A4 | |
| SCHEMBL6961100 | 0.82 | NPC1 (0.39) | AGTR1AGTR2 | |
| SCHEMBL4609709 | 0.79 | LTB4R2 (0.60) | LTB4R2CYP3A4CYP2C19 | |
| SCHEMBL8260354 | 0.78 | LTB4R2 (0.52) | LTB4R2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5157040-A | Treatment of hypertension, ocular hypertension and some CNS disorders | MERCK & CO., INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0507594-A1 | Substituted quinolines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-10-07 | — | — | EP | disclosed |